Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
AssigneesThe United States of America AS Represented By the, Secretary, Department of Health and Human Services
InventorsJeffrey Schlom, Scott Abrams
Life of this patent
Estimating the term…
Abstract
Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in vivo-primed CD8+ CTL precursors.
Claims43
-9. (canceled)
A mutant ras peptide consisting of:
- Xaa1 Leu Xaa2 Val Val Gly Ala Xaa3 Gly Val Gly Lys Ser (SEQ ID NO:
- 15) or a fragment thereof;
- wherein the peptide consists of 8 to 13 amino acids;
- wherein the peptide includes Xaa1;
- wherein Xaa1 is lysine or tyrosine;
- wherein Xaa2 is selected from the group consisting of valine, tryptophan, leucine, tyrosine, and phenylalanine;
- wherein Xaa3 is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, and serine;
- wherein when Xaa2 is valine, Xaa1 is tyrosine;
- and
- wherein the peptide elicits peptide-specific human CD8+ cytotoxic T lymphocytes.
11-24. (canceled)
28-29. (canceled)
(canceled)
The pharmaceutical composition according to 40, wherein the antigen presenting cell is a dendritic cell, a B lymphocyte, a monocyte or a macrophage.
Dependencies are inferred from the claim text.